Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy

NCT ID: NCT01936662

Last Updated: 2016-05-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Esophagogastroduodenoscopy (EGD) is a relatively common procedure in pediatric patients undergoing evaluation for various gastrointestinal ailments. The procedure itself, with or without associated biopsies, is relatively short in length. Unlike adults, who regularly undergo this procedure with conscious sedation, children most often require general anesthesia. While safe and effective, endotracheal tracheal tube (ETT) intubation of children for EGD can result in delayed awakening and slow room turnover, particularly when intravenous medications are required for intubation. Laryngeal mask airway (LMA) is an alternative to intubation, which permits removal before full awakening.

Although considered a safe alternative to tracheal intubation in appropriate cases, disadvantages of the LMA have been reported including kinking, occluding view of the surgical field, failure of placement requiring tracheal intubation, aspiration of gastric contents, desaturation, and laryngospasm. The study was designed to determine whether use of an LMA for EGD could reduce operating room time, while providing satisfactory conditions for the endoscopist, and an equivalent side effect and safety profile as compared to ETT in otherwise healthy children with gastrointestinal complaints

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Study design The study will be randomized, controlled, and prospective in design.
2. Comparison groups The two comparison groups will be:

1. Laryngeal Mask Airway Group (LMA), N = 42 LMA will be used as the intraoperative airway device.
2. Endotracheal Tube Group (ETT), N = 42 ETT will be used as the intraoperative airway device.
3. Study and timeline of interventions

1. Preoperative: All patients enrolled in this study will receive a standard preoperative dose of oral midazolam 0.5 mg/kg up to 15 mg, 15 to 30 minutes prior to anesthetic induction.
2. Intraoperative: Subjects will all undergo induction of anesthesia by inhalation of sevoflurane and oxygen. An intravenous catheter (IV) will be placed, followed by lidocaine 2mg/kg IV. The airway device will be placed (LMA or ETT). As required for the procedure, the subject will be placed in a left lateral decubitus (left side down) position. Maintenance of anesthesia will be provided with sevoflurane at a concentration of 1.5-2 MAC, or higher if deemed appropriate for the clinical setting as judged by the anesthesiologist. All participants will be given the anti-nausea medicine ondansetron 0.1mg/kg (maximum 4 mg) after placement of the airway device. When the endoscope is removed at the completion of the procedure, the patient will be returned to the supine position. The sevoflurane will be discontinued and the airway device will be removed when the anesthesiologist deems it appropriate. Prior to leaving the OR, the anesthesiologist may give pain or anti-anxiety medicine as needed.
3. Postoperative: All patients will receive routine PACU care. Pain and anxiety scores will be recorded according to routine PACU practice. Medication for pain, nausea, and anxiety will be given according to the judgment of the anesthesiologist.
4. Measured end-points:

i. Time from induction of anesthesia to placement of the airway device ii. Time from end of procedure to arrival in the PACU iii. Time spent in the PACU iv. Overall time from arrival in the OR to discharge home v. Vomiting after the procedure vi. Nausea requiring medicine after the procedure vii. Lowest oxygen saturation level during or after the procedure viii. Highest concentration of sevoflurane during the procedure ix. Highest pain level after the procedure x. Amount of pain medicine given xi. Adverse events xii. Satisfaction level of the doctor doing the EGD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Airway Morbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Largyngeal Mask Airway for EGD procedure

Patients randomized to LMA to maintain airway through EGD procedure

Group Type EXPERIMENTAL

LMA

Intervention Type DEVICE

Patients randomized to the LMA group had their airways maintained with a LMA device

Endotracheal Tube for EGD procedure

Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital

Group Type ACTIVE_COMPARATOR

ETT

Intervention Type DEVICE

Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LMA

Patients randomized to the LMA group had their airways maintained with a LMA device

Intervention Type DEVICE

ETT

Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled for Esophagogastroduodenoscopy, with or without biopsies
* Have been informed of the nature of the study and informed consent has been obtained from the legally responsible
* Have provided assent in accordance with Institutional Review Board requirements
* Are able to complete pain assessment evaluations as determined by preoperative evaluations

Exclusion Criteria

* • Abnormal/difficult airway

* Symptomatic obstructive sleep apnea
* Risk of aspiration of stomach contents
* Upper respiratory infection within last 14 days
* Allergy to lidocaine or ondansetron
* EGD procedures associated with the need to exclude ondansetron administration
* BMI \>85th percentile for age
* Are unable to communicate effectively with study personnel
* Have a positive urine pregnancy test (menstruating females only at screening
Minimum Eligible Age

3 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indiana University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Micahel Acquaviva, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Riley Hospital for Children at IU Health

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Acquaviva MA, Horn ND, Gupta SK. Endotracheal intubation versus laryngeal mask airway for esophagogastroduodenoscopy in children. J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):54-6. doi: 10.1097/MPG.0000000000000348.

Reference Type DERIVED
PMID: 24637966 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1011002885

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pediatric Intubation
NCT02289872 COMPLETED NA